Biolargo, Inc.

Name: Biolargo, Inc. standardized financial statements, quarterly
Creator: Listed

BLGOOTCCIK 880242MaterialsFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.2m, Q2 FY2026

Operating income−$3.7m, Q2 FY2026

Net income−$4.0m, Q2 FY2026

Biolargo, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	2,672	4,370	4,760	5,014	4,351	3,657	3,269	2,777	1,103	617	1,115	1,248
Cost of revenue	$k	1,237	2,282	2,514	2,877	2,629	1,907	1,781	1,356	731	489	657	573
Gross profit	$k	1,435	2,088	2,246	2,137	1,722	1,750	1,488	1,421	372	128	458	675
Research and development	$k	694	436	784	623	690	784	791	535	615	659	907	1,088
Selling, general and administrative	$k	2,278	2,264	2,225	2,404	2,093	2,582	2,522	2,688	3,088	3,429	2,755	3,315
Operating income	$k	(1,537)	(1,006)	(763)	(890)	(1,061)	(1,616)	(1,862)	(1,802)	(7,180)	(4,011)	(3,204)	(3,728)
Interest expense	$k	12.0	19.0	12.0	2.0	13.0	37.0	93.0	115	144	188	188	285
Net income	$k	(1,508)	(1,020)	(775)	(780)	(1,060)	(1,732)	(1,921)	(1,882)	(7,244)	(4,142)	(3,405)	(4,000)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	(0.00)	not reported	(0.00)	(0.00)	(0.00)	not reported	0.00	(0.00)	(0.02)	not reported	(0.01)	(0.01)

Balance sheet

Cash and equivalents$2.2m, Q2 FY2026

Long-term debt$2.1m, FY2025

Shareholders' equity−$1.9m, Q2 FY2026

Biolargo, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	3.0	3.5	4.3	4.8	3.9	3.5	2.6	3.5	4.5	3.9	4.1	2.2
Current assets	$m	4.7	6.4	7.2	7.1	7.4	7.1	7.2	9.2	5.8	5.1	5.4	3.5
Total assets	$m	6.5	8.2	9.8	10.1	10.3	10.5	10.5	12.5	9.1	8.3	8.6	6.7
Current liabilities	$m	1.7	2.7	3.4	3.0	3.2	2.6	3.4	4.1	3.5	5.1	4.9	4.8
Total liabilities	$m	2.7	4.0	4.7	4.2	4.3	4.5	5.4	6.4	5.9	6.8	8.8	9.4
Long-term debt	$m	0.3	0.3	0.3	0.2	0.2	1.1	not reported	not reported	not reported	2.1	not reported	not reported
Current portion of debt	$m	0.1	0.1	0.1	0.1	0.1	0.1	not reported	0.1	0.1	not reported	not reported	not reported
Shareholders' equity	$m	7.1	6.8	8.1	6.0	8.6	8.9	7.6	8.8	6.6	4.0	1.8	(1.9)

Cash flow

Operating cash flow−$3.1m, Q2 FY2026

Biolargo, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(836)	(2.0)	481	(151)	(1,620)	(1,916)	(1,830)	(2,118)	(2,759)	(1,590)	(2,917)	(3,056)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. Listed shows no prices and gives no investment advice.